Proteoglycan degrading mutants for treatment of cns
AssigneeAcorda Therapeutics, Inc.
InventorsElliott A. GRUSKIN, Rohini D'SOUZA, Gargi ROY, Anthony O. CAGGIANO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
Claims9
A mutant chondroitinase AC protein comprising an amino acid sequence of chondroitinase AC (SEQ ID NO:
- 5) truncated by a deletion of about 1 to about 100 amino acids from the N-terminus.
A composition comprising a mutant chondroitinase AC protein comprising an amino acid sequence of chondroitinase AC (SEQ ID NO:
- 5) truncated by a deletion of about 1 to about 100 amino acids from the N-terminus.
A recombinant nucleic acid comprising a sequence encoding a mutant chondroitinase AC protein, wherein the mutant chondroitinase AC protein comprises an amino acid sequence of SEQ ID NO:
- 5 truncated by a deletion of about 1 to about 100 amino acids from the N-terminus.
Dependencies are inferred from the claim text.